Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy (NJBMR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01905969
Recruitment Status : Unknown
Verified March 2015 by Satoshi Nishizuka, Iwate Medical University.
Recruitment status was:  Active, not recruiting
First Posted : July 23, 2013
Last Update Posted : March 25, 2015
Sponsor:
Information provided by (Responsible Party):
Satoshi Nishizuka, Iwate Medical University

Brief Summary:
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival. However, there are still considerable number of patients experience relapse even after adjuvant chemotherapy. In an attempt to select patients who really benefit the postoperative adjuvant chemotherapy, we have identified potential biomarkers (NF-kappaB/JNK) from cell line panel screening followed by immunohistochemical validation. In the present study, we further validate the significance of the biomarkers in a larger set of clinical samples to see if chemotherapeutic response can be determined immediately after surgery.

Condition or disease
Gastric Cancer

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1
Study Start Date : October 2012
Actual Primary Completion Date : March 2014
Estimated Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Group/Cohort
Biomarker positive
NF-kB(+)/JNK(-) in curatively removed specimens
Biomarker negative
NF-kB(-)/JNK(+) in curatively removed specimens



Primary Outcome Measures :
  1. Relapse free survival [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Archived paraffin blocks


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This is a retrospective study. Data analyses are based on archived record and materials of gastric cancer patients whose treatment was curative surgery followed by adjuvant chemotherapy with S-1.
Criteria

Inclusion Criteria:

  • Pathologically confirmed gastric cancer.
  • Operated before November 2009.
  • Stage Ib/II(except for T1, T3N0)/III.
  • Received postoperative (R0) adjuvant chemotherapy (S-1).
  • Not received postoperative (R0) adjuvant chemotherapy (surgery alone).
  • Signed informed consent to provide paraffin embedded tissue of removed specimens.

Exclusion Criteria:

  • With advanced neoplastic lesions other than gastric cancer.
  • Paraffin embedded tissue is not available.
  • Unknown S-1 treatment condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01905969


Locations
Layout table for location information
Japan
Iwate Medical University School of Medicine
Morioka, Iwate, Japan, 020-8505
Sponsors and Collaborators
Iwate Medical University
Publications:
Layout table for additonal information
Responsible Party: Satoshi Nishizuka, Assistant Professor, Iwate Medical University
ClinicalTrials.gov Identifier: NCT01905969    
Other Study ID Numbers: MIAST-NJBMR-12
First Posted: July 23, 2013    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: March 2015
Keywords provided by Satoshi Nishizuka, Iwate Medical University:
Gastric caner, adjuvant chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases